Looking ahead to the pivotal trial in triple-negative breast cancer with IMMU-132, slated to begin this summer, Immunomedics Inc. stands as "the only game in town at the moment this far along that has an antibody that targets this [TROP-2] receptor," Chau Cheng, director of investor relations, told BioWorld Today.
Removing senescent cells from middle-aged mice by pushing them into apoptosis lengthened the life span of the animals by 25 to 35 percent, researchers from the Mayo Clinic have reported.
Like travelers encountering an oasis after a spiritless trek through the desert, investors rushed Wednesday to shares of Chinese cancer drug developer Beigene Ltd. and Cambridge, Mass.-based genome-editing company Editas Medicine Inc. as they became the first two companies – in any sector – to price U.S. IPOs this year.
- Livid lawmakers grill Martin Shkreli, Valeant Pharma on high drug prices
- Taking giant 'STEP ONE,' Viacyte absorbs assets of Janssen Betalogics
- Patchwork tilt? Corium's Aricept PK data hinting skin win after Japan fail
- VCs blame U.K. tech transfer offices for gap in translating research
- CMS biosimilar payment plan nearly flunks House ...
- South Korea continues to boost biopharma sector, tightening review process
- Huya, Eisai join forces in $280M deal for HDAC inhibitor HBI-8000
- Adagene adds $28M in series B for antibody discovery, development
- 'A lot of firsts,' as Korean firm Viromed advances gene therapy
- 3SBio buys a larger stake in CP Guojian Pharma f...
It has been a long journey but the end is finally within sight for the large biopharmaceutical companies that have had to traverse steep patent cliffs along the way, which served to play havoc with their bottom-lines. It is estimated that a total of more than $300 billion of prescription drugs sales will have lost their patent exclusivity and become exposed to generic competition before the worst is over in a couple of years.
PARIS – With increasing reports of neurological disorders and neonatal malformations caused by the Zika virus from 22 countries, the World Health Organization (WHO) has declared an international emergency, calling it an “extraordinary event.”
The WHO estimated there could be up to 4 million cases of Zika in the Americas in the next year, but no recommendations were made to restrict travel or trade. The WHO alert puts Zika in the same category of concern as Ebola.READ MORE »
- Axon regeneration promoted by neuronal activity enhancement »
- HIV reservoir replenished by ongoing viral replication »
- Transgenic monkeys model autism spectrum disorder »
- Targeting receptor heterodimers may offer new antihypertensives »
- Macrophages proliferate via embryonic stem cell transcription networks »
- PD-1 blockers improve cognition in Alzheimer's mice, study shows »
- Antifungal drug could prove to be answer to multidrug resistance »
- Sharing is a bad idea for TB-infected immune cells »
- Failed Fragile X trial holds design lessons »
- No joy in Bio-villeDecember 30, 2015 | 10:48 PM | Posted by: Mari Serebrov
- May the fun be with you: BioWorld’s 9th annual Holiday Gift GuideDecember 30, 2015 | 2:24 AM | Posted by: Marie Powers
- An inconvenient truthNovember 11, 2015 | 12:15 AM | Posted by: Mari Serebrov
- Precision medicine in the real worldOctober 01, 2015 | 8:32 PM | Posted by: Mari Serebrov
- Better Rx needed to treat drugmakers’ PR maladySeptember 22, 2015 | 7:06 PM | Posted by: Mari Serebrov
Partners in Focus
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter